Clinical trial
A Prospective, Randomized, Controlled Trial Comparing Cytal Wound Matrix 1-Layer to Standard of Care (SOC) in the Management of Diabetic Foot Ulcers (DFUs)
NCT03626623 is registered in ClinicalTrials.gov with Integra LifeSciences Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Controlled Trial Comparing Cytal Wound Matrix 1-Layer to Standard of Care (SOC) in the Management of Diabetic Foot Ulcers (DFUs)
- Lead sponsor
- Integra LifeSciences Corporation
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- May 21, 2019
- Completion date
- February 18, 2020
- Enrollment
- 15 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.